Clinigen Group plc (AIM: CLIN) has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Swiss-based Novartis International AG (VTX: NOVN), the pharmaceutical company announced on Tuesday.
Financial terms of the deal were not disclosed.
Proleukin is licensed in around 20 countries and is primarily indicated for use in metastatic renal cell carcinoma, as well as for metastatic melanoma in certain markets. The drug is also currently being investigated in clinical trials at varying dose levels and in combination with other licensed and developmental pharmaceutical products.
Clinigen said it will seek to revitalise sales of Proleukin by working with healthcare professionals to ensure its benefit to patients is well understood and by making the drug available to those who need it. The company is also investigating the opportunity to develop new dosage presentations and potential product combinations.
Clinigen views Proleukin as a good fit with its current Commercial Medicines portfolio of products in the oncology and infectious disease therapy areas.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial